title: Inducible HSP70 mediates delayed cardioprotection via U-50488H pretreatment in rat ventricular myocytes.
abstract: To test the hypothesis that heat-shock proteins (HSPs) mediate delayed cardioprotection of prior kappa-opioid receptor (kappa-OR) stimulation, we first correlated cellular injury and viability with the expression of HSP70s in isolated rat ventricular myocytes subjected to prior kappa-OR stimulation with the selective agonist trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (U-50488H) and delayed lethal simulated ischemia (LSI). Cell injury and viability were indicated by lactate dehydrogenase release and trypan blue exclusion, respectively. The reduced injury and increased viability after pretreatment with U-50488H were concentration dependent and correlated directly with the expression of both stress-inducible (HSP70) and constitutive (HSC70) proteins. The effects mimic those with metabolic inhibition preconditioning (MIP). The cardioprotection against LSI by pretreatment with U-50488H and MIP was abolished and antagonized, respectively, via blockade of the kappa-OR by its selective antagonist, nor-binaltorphimine. We also found that blockade of the production of HSP70 but not HSC70 blocked the inhibitory effect of pretreatment with U-50488H on injury and viability. These observations provide evidence that stress-inducible HSP70 mediates delayed cardioprotection of prior kappa-OR stimulation.
authors.affiliation: Department of Physiology, Faculty of Medicine, University of Hong Kong, Hong Kong, China.
authors.forename: J J
authors.initials: JJ
authors.lastname: Zhou
authors.forename: J M
authors.initials: JM
authors.lastname: Pei
authors.forename: G Y
authors.initials: GY
authors.lastname: Wang
authors.forename: S
authors.initials: S
authors.lastname: Wu
authors.forename: W P
authors.initials: WP
authors.lastname: Wang
authors.forename: C H
authors.initials: CH
authors.lastname: Cho
authors.forename: T M
authors.initials: TM
authors.lastname: Wong
mesh_terms: D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000494:pharmacology*; D000818:Animals; D018840:HSP70 Heat-Shock Proteins / Q000235:genetics / Q000502:physiology*; D006321:Heart / Q000187:drug effects* / Q000502:physiology*; D006352:Heart Ventricles; D019157:Ischemic Preconditioning, Myocardial; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D017202:Myocardial Ischemia / Q000473:pathology; D009206:Myocardium / Q000166:cytology; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D020011:Protective Agents / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000037:antagonists & inhibitors
chemical_list: D018840:HSP70 Heat-Shock Proteins; D009292:Narcotic Antagonists; D016376:Oligonucleotides, Antisense; D020011:Protective Agents; D017473:Receptors, Opioid, kappa; C051844:norbinaltorphimine; D009271:Naltrexone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D007770:L-Lactate Dehydrogenase